Symbiotec Pharmalab Ltd Guidance Report - SOIC x StockScans Report
as of Nov 2026
- Conjugated estrogen products in vaginal cream and oral tablets
Pending - At the DRHP, the company stated intent to commercialise conjugated estrogen products in vaginal cream and oral tablets, leveraging a distribution partnership with a global pharmaceutical company. As of Q2 FY27, the Premarin launch is a few years away pending partner formulation development, with no commercial impact expected in coming quarters.
- IPO net proceeds ₹112.5 cr for debt repayment, deployed in Fiscal 2027
On track - At the DRHP, the company proposed to utilise ₹112.5 cr from Net Proceeds towards repayment/prepayment of outstanding borrowings, with estimated deployment in Fiscal 2027. The monitoring agency report as of November 2026 shows no deviation, and net debt fell from ₹398 cr (30 June 2026) to ₹314 cr (30 September 2026).
- Two DCV products launch in Fiscal 2026
Missed - At the DRHP, management stated two DCV products (methylprednisolone sodium succinate injection and hydrocortisone sodium succinate) had an expected launch in fiscal 2026. No launch occurred in FY26; the first ANDA was filed and accepted by USFDA in September 2026, with FDA approval expected by end of calendar year 2027 and commercial supplies next year.
- Biologics facility (14 KL, Ujjain) for GLP-1 and Insulin
Partial - The DRHP stated the 14 KL biologics facility at Ujjain would be commissioned in Fiscal 2026, catering to GLP-1 and Insulin; the Q1 FY27 PPT showed it under construction. It is not yet commissioned as of Q2 FY27; commissioning is expected in Q4 FY27 after a couple of months' delay, with regulatory filing in Q4 FY27/Q1 FY28.
- Vegan Vitamin D3 plant ready by end of FY27, sales early next fiscal year
On track - At the Q2 FY27 call, management stated the vegan Vitamin D3 plant's construction and qualification would finish by end of this fiscal year, with sales early next fiscal year at least in nutraceutical and veterinary markets. The plant is under construction at advanced stages, with no completion or sales yet disclosed.
- US alternate protein take-or-pay contract - commercial batches Q1 FY28
On track - At the Q2 FY27 call, management stated commercial batches for the US alternate protein 10-year take-or-pay contract were expected in Q1 of FY28, with the plant needing another 5-6 months. The agreement is in place and project capex on track, with no commercial batch production yet as of Q2 FY27.
- API business growth - high single digits for next several years
On track - At the Q1 FY27 call, management guided API business growth in high single digits for the next several years, a conservative view; at Q2 FY27 this was restated as high single digits, sometimes low double digit. Q1 FY27 API revenue grew 6% YoY and Q2 FY27 grew 16% YoY, with H1 FY27 at +11% YoY.
- Capex - minimum ₹200-250 cr each year for two to three years
On track - At the Q1 FY27 call, management guided minimum ₹200 cr to ₹250 cr each year for the next two to three years, funded from operating cash flows; at Q2 FY27 this was restated as ₹200 to ₹300 cr every year. H1 FY27 capex was ₹113 cr, an annualised run-rate of ₹226 cr within the guided range.
- Phase 1 biomanufacturing - 600 KL brownfield expansion, construction from Q3 FY27
On track - At the Q1 FY27 call, management guided a 600 KL brownfield Phase 1 expansion (on top of 400 KL Phase 0), needing 15 to 18 months to build with construction starting Q3 FY27. At Q2 FY27 this was revised to 750 KL for the European customer, whose 10-year take-or-pay agreement was signed 30th September 2026, with initial manufacturing in Q4 and a 12-15 month build.
- DCV definitive agreement with US pharma multinational - signing early Q3 FY27
Delivered - At the Q1 FY27 call, management said the definitive agreement with a large US-based pharmaceutical multinational for the DCV platform was "just a whisker away" and expected to be signed in early Q3 FY27. On 30th September 2026, a long-term agreement was signed with a leading global company for 2 complex injectable DCV products for the US market.
- API gross margins around 60% base, EBITDA near 30%
Delivered - At the Q1 FY27 call, management guided API gross margins to continue around 60% as the base, with EBITDA margins very close to 30% maintained. Q1 FY27 API gross margin was 60%+, and Q2 FY27 gross margins held over 60% with EBITDA margins stable around 30% through Q2 and H1.
- New business revenues - biotech CDMO and injectables within 6-12 months
On track - At the Q1 FY27 call, management stated revenues from the two new businesses (biotech CDMO and injectables) were expected in the next 6 to 12 months; at Q2 FY27, DCV supply revenues were slated from next fiscal year and first biotech CDMO revenues from Q4 FY27. ₹53 cr of injectables milestone revenue was recognised in Q2 FY27, with no biotech CDMO revenue yet.
- FY27 consolidated EBITDA growth of 25%, ±5%
On track - At the Q1 FY27 call, management guided FY27 consolidated EBITDA growth of 25% with a possible ±5% variation, "with a high degree of confidence"; this was reaffirmed at Q2 FY27. H1 FY27 consolidated EBITDA was ₹140 cr, +29% YoY, with Q2 FY27 at ₹94 cr, +88% YoY; the full year is not yet complete.
- FY27 consolidated revenue growth of 20%, ±5%
On track - At the Q1 FY27 call, management guided FY27 consolidated revenue growth of 20% with a possible ±5% variation due to global uncertainties, "with a high degree of confidence"; this was reaffirmed at Q2 FY27. H1 FY27 consolidated revenue was ₹498 cr, +25% YoY, with Q2 FY27 at ₹280 cr, +43% YoY; the full year is not yet complete.